Specifically, the somatic mutations in PLCG1 gene have been linked to angiosarcoma and T-cell lymphomas while somatic mutations in PLCG2 contribute to drug (Ibrutinib) resistance in chronic lymphocytic leukaemia (CLL). This evidence concerns the gene PLCG1 and B-cell chronic lymphocytic leukemia.